<DOC>
	<DOCNO>NCT02586038</DOCNO>
	<brief_summary>This study evaluate safety efficacy MLN-DEXAMETHASONE , MLN-DEXAMETHASONE-CYCLOPHOSPHAMIDE , MLN-DEXAMETHASONE-BENDAMUSTINE MLN- THALIDOMIDE-DEXAMETHASONE induction combination , follow MLN maintenance newly diagnose elderly Multiple Myeloma patient . 260 patient , male female , old 65 year old young consider eligible high-dose chemotherapy transplantation , enrol different site , take part study . The duration study approximately 5 year .</brief_summary>
	<brief_title>Study MLN9708 Plus Oral Dexamethasone Plus Oral Cyclophosphamide Dexamethasone Plus Bendamustine Dexamethasone Plus Oral Thalidomide Dexamethasone Followed Maintenance With MLN9708 Newly Diagnosed Elderly Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal surgically sterilize willing use two acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study . Newly diagnose MM base standard CRAB criterion ( see Appendix 12.2 ) . Age ≥ 65 year old young eligible transplantation . Patient measurable disease , define follow : quantifiable serum monoclonal protein ( Mprotein ) value ( generally , necessarily , ≥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result Eastern Cooperative Oncology Group ( ECOG ) performance status and/or performance status 0 , 1 , 2 Clinical laboratory value within 30 day enrolment : platelet count ≥ 75 x 109/mm3 ( Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment ) haemoglobin ≥ 8 g/dL absolute neutrophil count ( ANC ) ≥ 1.0 x109/mm3 AST ALT ≤ 3 time upper limit normal total bilirubin ≤ 1.5 time upper limit normal clearance creatinine ≥ 30 ml/min Pregnant lactating female . Serious medical condition , laboratory abnormality psychiatric illness prevent subject enrolment place subject unacceptable risk . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid &lt; equivalent dexamethasone 40 mg/day 4 day ) Clinical active infectious hepatitis type A , B , C HIV ( HBVDNA HCVRNA analyse evaluate cell proliferation virus ; antiHIV antibody must negative ) . Acute active infection require antibiotic infiltrative pulmonary disease Peripheral neuropathy neuropatic pain grade 2 high , defined National Cancer Institute Common Toxicity Criteria ( NCI CTC ) 4.03 Contraindication require drug supportive treatment Invasive malignancy within past 3 year Systemic treatment strong inhibitor CYP1A2 ( fluvoxamine , enoxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , posaconazole ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use Ginkgo biloba St. John 's wort within 14 day first dose study treatment ( see Appendix 12.12 ) . Diagnosis Waldenstrom 's macroglobulinemia , primary amyloidosis , myelodysplastic syndrome , myeloproliferative syndrome . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month . Known allergy study medication , analogue , excipients various formulation .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>